[8-K] Tonix Pharmaceuticals Holding Corp. Reports Material Event

Rhea-AI Filing Summary

Tonix Pharmaceuticals Holding Corp. reported that it announced operating results for the quarter ended June 30, 2025. The company states a press release discussing those results is filed as Exhibit 99.01 and is incorporated by reference into this report. The filing confirms Tonix's common stock trades under the symbol TNXP on The NASDAQ Capital Market.

The filing is a notice of the release of operating results rather than detailed financial statements within the form itself; the cover page interactive XBRL file is referenced as Exhibit 104, and the report is signed by the company’s Chief Financial Officer, Bradley Saenger.

Insights

Financial Analyst

TL;DR: Routine earnings disclosure filed; no financial detail in the form itself, press release attached as exhibit.

The 8-K notifies investors that the company released its operating results for the quarter ended June 30, 2025, and includes the press release as Exhibit 99.01. Because the form does not contain numerical results or detailed financial statements, the filing primarily serves as a distribution and disclosure mechanism. Investors must review the attached press release and any accompanying XBRL data for substantive metrics such as revenue, net income, or cash flow.

Corporate Governance Expert

TL;DR: Disclosure follows standard reporting practices; signature by CFO confirms formal filing authority.

The document follows standard Section 2.02 and 9.01 disclosure conventions by notifying the market of released results and formally attaching the press release as an exhibit. The inclusion of the interactive XBRL cover page indicates preparer intent for machine-readable disclosure. The signature by the Chief Financial Officer confirms internal authorization, but the filing itself contains no material operational or governance changes.

false 0001430306 0001430306 2025-08-11 2025-08-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (date of earliest event reported): August 11, 2025

TONIX PHARMACEUTICALS HOLDING CORP. 

(Exact name of registrant as specified in its charter)

Nevada		001-36019		26-1434750
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

26 Main Street, Chatham, New Jersey 07928

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (862) 799-8599

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	TNXP	The NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). 

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 11, 2025, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced its operating results for the quarter ended June 30, 2025. A copy of the press release that discusses these matters is filed as Exhibit 99.01 to, and incorporated by reference in, this report.

Item 9.01 Financial Statements and Exhibits.

(d)		Exhibit No.		Description
		99.01		Press Release of the Company, dated August 11, 2025
		104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	TONIX PHARMACEUTICALS HOLDING CORP.
Date: August 11, 2025	By:	/s/ Bradley Saenger
		Bradley Saenger
		Chief Financial Officer

FAQ

What did Tonix Pharmaceuticals (TNXP) report in this 8-K?

The company announced operating results for the quarter ended June 30, 2025 and filed a related press release as Exhibit 99.01.

Where is Tonix Pharmaceuticals (TNXP) listed?

Tonix's common stock trades under the symbol TNXP on The NASDAQ Capital Market.

Does this 8-K include detailed financial statements or results?

No detailed financial statements are included in the form; the press release (Exhibit 99.01) and the interactive XBRL cover page (Exhibit 104) are referenced for details.

Who signed the 8-K for Tonix Pharmaceuticals?

The report is signed on the company’s behalf by Bradley Saenger, Chief Financial Officer.

How can I find the operating results mentioned in the filing?

Review the press release attached as Exhibit 99.01 to this 8-K for the company’s detailed operating results and related commentary.